| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | -0.023 | 0.9 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.02 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | -0.02 | 0.9 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.9 |